- Home
- TRVI vs CGC Comparison
TRVI vs CGC Comparison
Compare TRVI & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- CGC
- Stock Information
- Founded
- TRVI 2011
- CGC 2009
- Country
- TRVI United States
- CGC Canada
- Employees
- TRVI N/A
- CGC N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- CGC Pharmaceuticals and Biotechnology
- Sector
- TRVI Health Care
- CGC Health Care
- Exchange
- TRVI Nasdaq
- CGC Nasdaq
- Market Cap
- TRVI 363.7M
- CGC 379.3M
- IPO Year
- TRVI 2019
- CGC N/A
- Fundamental
- Price
- TRVI $4.60
- CGC $1.63
- Analyst Decision
- TRVI Strong Buy
- CGC Sell
- Analyst Count
- TRVI 8
- CGC 1
- Target Price
- TRVI $9.31
- CGC $2.00
- AVG Volume (30 Days)
- TRVI 739.7K
- CGC 10.5M
- Earning Date
- TRVI 03-19-2025
- CGC 02-07-2025
- Dividend Yield
- TRVI N/A
- CGC N/A
- EPS Growth
- TRVI N/A
- CGC N/A
- EPS
- TRVI N/A
- CGC N/A
- Revenue
- TRVI N/A
- CGC $192,343,833.00
- Revenue This Year
- TRVI N/A
- CGC N/A
- Revenue Next Year
- TRVI N/A
- CGC $7.40
- P/E Ratio
- TRVI N/A
- CGC N/A
- Revenue Growth
- TRVI N/A
- CGC N/A
- 52 Week Low
- TRVI $2.30
- CGC $1.58
- 52 Week High
- TRVI $5.05
- CGC $14.92
- Technical
- Relative Strength Index (RSI)
- TRVI 62.80
- CGC 34.35
- Support Level
- TRVI $3.93
- CGC $1.58
- Resistance Level
- TRVI $4.14
- CGC $1.97
- Average True Range (ATR)
- TRVI 0.29
- CGC 0.19
- MACD
- TRVI 0.06
- CGC -0.02
- Stochastic Oscillator
- TRVI 64.82
- CGC 3.79
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About CGC Canopy Growth Corporation
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Doja, 7ACRES, Tweed, and Deep Space. Its non-THC products include skincare products under Martha Stewart CBD and Storz & Bickel vaporizers. Canopy growth merged its US assets into a separately operated holding company, Canopy USA, which will not be consolidated into the Canadian company's financials.